| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 5
| Issue : 4 | Page : 366-373 |
|
|
Plant-based vaccines: Potentiality against severe acute respiratory syndrome coronavirus 2
Pramita Sharma1, Himel Mondal2, Shaikat Mondal3, Rabindranath Majumder4
1 Centre for Healthcare Science and Technology, Indian Institute of Engineering Science and Technology, Howrah; Department of Zoology, Hooghly Mohsin College (Affiliated to University of Burdwan), Chinsurah, West Bengal, India
2 Department of Physiology, Santiniketan Medical College, Bolpur, West Bengal, India
3 Department of Physiology, Raiganj Government Medical College, Raiganj, West Bengal, India
4 Centre for Healthcare Science and Technology, Indian Institute of Engineering Science and Technology, Howrah, West Bengal, India
Correspondence Address:
Rabindranath Majumder
Centre for Healthcare Science and Technology, Indian Institute of Engineering Science and Technology, Shibpur, Howrah - 711 103, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | 3 |
DOI: 10.4103/bbrj.bbrj_185_21
|
|
|
The pandemic of novel coronavirus disease-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has stimulated scientists from different backgrounds to gear up on developing vaccines against the virus. Several antigenic epitopes of the virus have the potential to induce an immunogenic response, among which viral spike protein (“S” protein) is considered to be the most suitable vaccine candidate. In this review, the latest progress in the field of plant molecular pharming (PMF), its application, limitations, and commercial initiatives toward the production of the SARS-CoV-2 vaccine have been discussed. Vaccine production by PMF has gained considerable attention these days and can be used for large-scale commercial production of antigenic proteins, antibodies, and other biopharmaceuticals. New age plant breeding techniques facilitated by CRISPR-Cas-based genome editing technology and next-generation sequencing methods also help to achieve greater precision and rapidity. Several unique advantages are offered by plant-based vaccine production techniques over that of the microbial or mammalian cell culture system. Virus-like particles and Agrobacterium-mediated transient somatic expression systems have a high potential for the large scale, cost-effective, and robust production of plant-derived vaccines against SARS-CoV-2.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
